

個人資料表

一、基本資料

簽 名：

填表日期：

中文姓名	楊 敏 瑜	英文姓名	Yang Ming-Yu		
			(Last Name)	(First Name)	(Middle Name)
國 籍	中華民國	性 別	<input type="checkbox"/> 男 <input checked="" type="checkbox"/> 女	出生日期	1961 年 05 月 25 日
聯絡/住宅地址	833 高雄縣鳥松鄉大埤路 123 號 高雄長庚兒童醫院 12 樓 長庚大學臨床醫學研究所				
聯絡電話	(公).07-7317123 ext. 8865				
傳真號碼	07-7311696	E-MAIL	yangmy@mail.cgu.edu.tw		

二、主要學歷 請填學士級以上之學歷或其他最高學歷均可，若仍在學者，請在學位欄填「肄業」。

畢／肄業學校	國別	主修學門系所	學位	起訖年月
高雄醫學大學	中華民國	醫學研究所	博士	2000/09 至 2004/01
田納西大學	美國	生物醫學研究所	碩士	1991/08 至 1994/12
輔仁大學	中華民國	生物系	學士	1981/10 至 1984/06

三、現職及與專長相關之經歷 指與研究相關之專任職務，請依任職之時間先後順序由最近者往前追溯。

服務機關	服務部門／系所	職稱	起訖年月
現職：長庚大學	臨床醫學研究所	助理教授	2008/11 ~ 迄今
經歷：			
輔英科技大學	生物技術系	助理教授	2004/08 至 2008/07
高雄醫學大學附設醫院	血液腫瘤內科	高級研究助理	2000/03 至 2004/07
高雄長庚兒童醫院	小兒科	臨床醫學資料師	1997/11 至 2000/02
高雄醫學院	血液腫瘤內科	高級研究助理	1996/08 至 1997/10
高雄醫學院	小兒科	研究助理	1995/12 至 1996/07
美國田納西大學	生物醫學研究所	助理研究員	1995/01 至 1995/10
高雄醫學院	婦產科	研究助理	1986/05 至 1991/05
台北三軍總醫院	小兒科	研究助理	1984/08 至 1986/04

四、專長 請自行填寫與研究方向有關之專長學門。

1. 分子生物學	2. 生物技術	3. 基礎生物醫學	4.
----------	---------	-----------	----

五、研究成果目錄：(一)

A、期刊論文 (*: Corresponding author)

(2017 JCR)

1. Chen RF, Chang CH, Wang CT, **Yang MY**, Wang CJ, Kuo YR. Modulation of VEGF and MAPK-related pathway involved in extracorporeal shockwave therapy accelerate diabetic wound healing. Wound Repair Regen. 2018 Nov 5. (In press)
(SCI; I.F.: 2.952; Surgery: 43/200 = 21.50%)
2. Lin YT, Wang HC, Chuang HC, Hsu YC, **Yang MY***, Chien CY*. Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts. J Mol Med. 2018. Dec; 96(12): 1407-1418.
(SCI; I.F.: 4.938; Medicine, Research & Experimental: 20/133 = 15.04%)
3. Hsu CM, Lin PM, Lin HC, Tsai YT, Tsai MS, Li SH, Wu CY, Yang YH, Lin SF*, **Yang MY***. NVP-BEZ235 attenuated cell proliferation and migration in the squamous-cell carcinoma of oral cavities and p70S6K inhibition mimics its effect. Int J Mol Sci. 2018. Nov; 19(11): 3546.
(SCI; IF: 3.687; Biochemistry & Molecular Biology: 90/292 = 30.82%)
4. Tsai HJ, Jiaang WT, Shih NY, Fletcher JA, Lin MJ, **Yang MY**, Chen CT, Hsu TJ, Wu CC, Lin HY, Chen LT. BPR1J373, a novel multi-targeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor. Cancer Sci. 2018 Nov; 109(11):3591-3601.
(SCI; I.F.: 4.372; Oncology: 65/222 = 29.28%)
5. Hsu CM, Lin PM, Tsai YT, Tsai MS, Tseng CH, Lin SF, **Yang MY***. NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin. Cell Death Discov. 2018 May 10;4:57.
6. Hsu CM, Lin PM, Chang JG, Lin HC, SH Li, Lin SF*, **Yang MY***. Upregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment. Oncotarget. 2017. Sep 26; 8(43): 74348-74358.
7. **Yang MY**, Hsiao HH, Liu YC, Hsu CM*, Lin SF*, Lin PM*. Phe354Leu polymorphism of LKB1 is a potential prognostic factor for cytogenetically normal acute myeloid leukemia. In Vivo. 2017. Sep-Oct; 31(5):841-847.
(SCI; I.F.: 1.116; Medicine, Research & Experimental: 114/133 = 85.71%)
8. Tsai MS, **Yang MY**, Chang GH, Tsai YT, Lin MH, Hsu CM*. Autologous thyroid cartilage graft implantation in medialization laryngoplasty: a modified approach for treating unilateral vocal fold paralysis. Sci Rep. 2017. Jul 6; 7(1):4790.
(SCI; IF: 4.122, Multidisciplinary Sciences: 12/64 = 19.35%)
9. Lin YT, Wang HC, Hsu YC, Cho CL, **Yang MY***, Chien CY*. Capsaicin induces autophagy and apoptosis in human nasopharyngeal carcinoma cells by downregulating the PI3K/AKT/mTOR pathway. Int J Mol Sci. 2017. Jun 23; 18(7): 1343.
(SCI; IF: 3.687; Biochemistry & Molecular Biology: 90/292 = 30.82%)
10. Chang LS, Lo MH, Li SC, **Yang MY***, Hsieh KS*, Kuo HC*. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease. Oncotarget. 2017. Jan 10; 8(2):2044-2052.
11. Yang MY*, Lin SF*. The role of circadian clock genes in leukemia. Transl Cancer Res. 2016. Aug; 5(S2): S196-S198. (SCI; IF: 1.200; Oncology: 209/222 = 94.14%)
12. Hsu CM, Lin PM, Lin HC, Lai CC, Yang CH, Lin SF*, Yang MY*. Altered expression of imprinted

- genes in squamous cell carcinoma of the head and neck. *Anticancer Res.* 2016. May; 36(5): 2251-2258. (SCI; IF: 1.865; Oncology: 182/222 = 81.98%)
13. **Yang MY**, Lin PM, Hsiao HH, Hsu JF, Lin HY, Hsu CM, Chen IY, Su SW, Liu YC, Lin SF*. Up-regulation of PER3 expression is correlated with better clinical outcome in acute leukemia. *Anticancer Res.* 2015. Dec; 35(12): 6615-6622. (SCI; IF: 1.865; Oncology: 182/222 = 81.98%)
 14. Yang CH, Hwang CF, **Yang MY**, Lin PM, Chuang JH. Expression of toll-like receptor genes in leukocytes of patients with sudden sensorineural hearing loss. *Laryngoscope.* 2015. Dec; 125:E382-E387. (SCI; IF: 2.442; Otorhinolaryngology: 12/41 = 29.27%)
 15. Lin HY, Hung CC, Chang YH, Lin MY, **Yang MY**, Liang SS, Liu W, Chen HC, Hwang SJ. Nonapnea sleep disorders in patients younger than 65 years are significantly associated with CKD: A nationwide population-based study. *PLoS One.* 2015 Oct 14; 10(10):e0140401. (SCI; IF: 2.766, Multidisciplinary Sciences: 15/64 = 24.19%)
 16. Yang CH, Hwang CF*, Lin PM, Chuang JH, Hsu CM, Lin SF, **Yang MY***. Sleep disturbance and altered expression of circadian clock genes in patients with sudden sensorineural hearing loss. *Medicine.* 2015. Jul; 94(26): e978. (SCI; IF: 2.028; Medicine, General & Internal: 56/154 = 36.36%)
 17. Lu CT, Hsu CM, Lin PM, Lai CC, Lin HC, Yang CH, Hsiao HH, Liu YC, Lin HYH, Lin SF*, **Yang MY***. The potential of SIRT6 and SIRT7 as circulating markers for head and neck squamous cell carcinoma. *Anticancer Res.* 2014. Dec; 34(12): 7137-7143. (SCI; IF: 1.865; Oncology: 182/222 = 81.98%)
 18. Kuo YR, Chen CC, Goto S, Huang YT, Tsai CC, **Yang MY**. Proteomic analysis in serum of rat hind-limb allograft tolerance induced by immunosuppressive therapy with adipose-derived stem cells. *Plast Reconstr Surg.* 2014 Dec; 134(6): 1213-1223. (SCI; I.F.: 3.475; Surgery: 30/200 = 15.00%)
 19. Liu YC, Hsiao HH, Yang WC, Liu TC, Chang CS, **Yang MY**, Lin PM, Hsu JF, Lee CP, Lin SF. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: The association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib. *Mol Carcinog.* 2014. Dec; 53(12): 951-959. (SCI; IF: 3.851; Oncology: 78/222 = 35.14%)
 20. Hsu CM, Lin PM, Lai CC, Lin HC, Lin SF*, **Yang MY***. PER1 and CLOCK are potential circulating biomarkers for head and neck squamous cell carcinoma. *Head & Neck.* 2014. Jul; 36(7): 1018-1026. (SCI; IF: 2.471; Otorhinolaryngology: 9/41 = 21.95%)
 21. Hu ML, Yeh KT, Lin PM, Hsu CM, Hsiao HH, Liu YC, Lin HY, Lin SF*, **Yang MY***. Deregulated expression of circadian clock genes in gastric cancer. *BMC Gastroenterol.* 2014. Apr 6; 14(1): 67. (SCI; I.F.: 2.731; Gastroenterology & Hepatology: 52/80 = 65.82%)
 22. **Yang MY**, Chiang YC, Huang YT, Chen CC, Wang FS, Wang CJ, Kuo YR. Serum proteomic analysis of extracorporeal shock wave therapy-enhanced diabetic wound healing in a streptozotocin-induced diabetes model. *Plast Reconstr Surg.* 2014. Jan; 133(1):59-68. (SCI; I.F.: 3.475; Surgery: 30/200 = 15.00%)
 23. Hsiao HH, Liu YC, **Yang MY**, Tsai YF, Liu TC, Chang CS, Lin SF. Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients. *Genet Mol Res.* 2013. Nov 18; 12(4): 5617-5622. (SCI; IF: 1.147; Genetics & Heredity: 146/166 = 87.95%)
 24. Liu YC, Hsiao HH, Lin PM, Yang WC, Chang CS, Liu TC, Hsu JF, **Yang MY**, Lin SF. Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. *Genet Mol Res.* 2013. Nov 11; 12(4):

5414-5423. (SCI; IF: 1.147; Genetics & Heredity: 146/166 = 87.95%)

25. Lin YC, Liao MY, Li TH, Chen GT, **Yang MY**, Wu SC. Application of real-time quantitative polymerase chain reaction to monitoring infection of classic swine fever virus and determining optimal harvest time in large-scale production. *Vaccine*. 2013. Nov. 12; 31(47): 5565-5571. (SCI; I.F.: 3.285; Medicine, Research & Experimental: 52/133 = 39.10%)
26. Yang WC, Tsai WC, Lin PM, **Yang MY**, Liu YC, Chang CS, Yu WH, Lin SF. Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia. *J Biomed Sci*. 2013. Aug 14; 20(1): 58. (SCI; IF: 3.466; Medicine, Research & Experimental: 46/133 = 34.59%)
27. Yang WC, Lin PM, **Yang MY**, Liu YC, Chang CS, Chou WC, Hsu JF, Huang CT, Cho SF, Yu WH, Lin SF. Higher lipocalin-2 expression may represent an independent favorable prognostic factor in cytogenetic-normal acute myeloid leukemia. *Leuk Lymphoma*. 2013. Aug; 54(8): 1614-1625. (SCI; IF: 2.644; Hematology: 34/71 = 47.89%)
28. Lai CC, Lin PM, Lin SF, Hsu CS, Lin HC, Hu ML, Hsu CM*, **Yang MY***. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. *Tumor Biol*. 2013. Jun; 34(3):1847-1854. (SCI; IF: 3.650; Oncology: 81/217 = 37.33%)
29. Hsu CM, Lin PM, Wang YM, Chen ZJ, Lin SF*, **Yang MY***. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. *Tumor Biol*. 2012. Dec; 33(6): 1933-1942. (SCI; IF: 3.650; Oncology: 81/217 = 37.33%)
30. Hsu CM*, Hsu CH., **Yang MY**, Lin HC, Lai CC, Hsu CY, Tsou YA. Glottal Insufficiency with Thyroid Cartilage Implantation: Our experience in eight patients. *Clin Otolaryngol*. 2012. Oct; 37(5): 399-405. (SCI; IF: 2.696; Otorhinolaryngology: 7/41 = 17.07%)
31. Liu YC, Yang YH, Hsiao HH, Yang WC, Liu TC, Chang CS, **Yang MY**, Lin PM, Hsu JF, Chang PY, Lin SF. Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies - A nationwide population-based matched-control study in Taiwan. *BMC Cancer*. 2012. Oct 31; 12(1): 503. (SCI; IF: 3.288; Oncology: 106/222 = 47.75%)
32. **Yang MY***, Lin PM, Liu YC, Hsiao HH, Yang WC, Hsu JF, Hsu CM, Lin SF*. Induction of cellular senescence by doxorubicin is associated with upregulated miR-375 and induction of autophagy in K562 cells. *PLoS ONE*. 2012. May; 7(5): e37205. (SCI; IF: 2.766, Multidisciplinary Sciences: 15/64 = 24.19%)
33. Hsu CM, Lin SF*, Lu CT, Lin PM, **Yang MY***. Altered expression of circadian clock genes in head and neck squamous cell carcinoma. *Tumor Biol*. 2012. Feb; 33(1): 149-155. (SCI; IF: 3.650; Oncology: 81/217 = 37.33%)
34. **Yang MY**, Yang WC, Lin PM, Hsu JF, Hsiao HH, Liu YC, Tsai HJ, Chang CS, Lin SF. Altered expression of circadian clock genes in human chronic myeloid leukemia. *J Biol Rhythm*. 2011. April; 6(2): 136-148. (SCI; I.F.: 3.906; Biology: 13/85 = 15.298%)
35. Lin YM, Chang JH, Yeh KT, **Yang MY**, Liu TC, Lin SF, Su WW, Chang JG. Disturbance of circadian gene expression in hepatocellular carcinoma. *Mol Carcinog*. 2008. 47(12): 925-933. (SCI; IF: 3.851; Oncology: 78/222 = 35.14%)
36. Hsiao HH, **Yang MY**, Liu YC, Lee CP, Yang WC, Liu TC, Chang CS, Lin SF. The association of JAK2(V617F) mutation and leukocytosis with thrombotic events in essential thrombocythemia. *Exp Hematol*. 2007. Oct 5; 35: 1698-1701. (SCI; I.F.: 2.436; Hematology: 37/71 = 52.11%)
37. **Yang MY**, Chang JG, Lin PM, Tang KP, Lin HYH, Liu TC, Hsiao HH, Liu YC, Lin SF. Down-regulation of circadian clock genes in chronic myeloid leukemia: Alternative methylation pattern of hPER3.

Cancer Sci. 2006. Dec; 97(12): 1298-1307. (SCI; I.F.: 4.372; Oncology: 65/222 = 29.28%)

38. Liu YC, Hsiao HH, Chang JG, **Yang MY**, Liu TC, Chang CS, Tseng SB, Tsai HJ, Lin SF. Usefulness of Quantitative Assessment of JunB Gene Expression as a Marker for Monitoring Chronic Myeloid Leukemia Patients Undergoing Imatinib Therapy. *Int J Hematol*. 2006. Dec; 84(5): 425-431. (SCI; I.F.:1.942, Hematology: 47/71 = 66.20%)
39. Shih HC, Choo KB, Chang TJ, **Yang MY**, Shih MC, Yeh KT, Liu TC, Lin SF, Chang JG. Disturbance of circadian gene expression in endometrial cancer: Detection by real-time quantitative RT-PCR. *Oncol Rep*. 2005. Dec; 14(6):1533- 1538. (SCI; I.F.: 2.976; Oncology: 123/222 = 55.41%)
40. Hsiao HH, **Yang MY**, Liu YC, Hsiao HP, Tseng SB, Chao MC, Liu TC, Lin SF. RBM15-MKL1 (OTT-MAL) fusion transcript in an adult acute myeloid leukemia patient. *Am J Hematol*. 2005. May; 79(1):43-45. (SCI; I.F.: 5.303; Hematology: 11/71 = 15.49%)
41. Yeh KT, **Yang MY**, Liu TC, Chen JC, Chan WL, Lin SF, Chang JG. Abnormal expression of period 1 (PER1) in endometrial carcinoma. *J Pathol*. 2005. May; 206(1):111-120. (SCI; I.F.: 6.253; Pathology: 5/79 = 6.33%)
42. Chang YS, Yeh KT, **Yang MY**, Liu TC, Lin SF, Chan WL, Chang JG. Abnormal expression of JUNB gene in hepatocellular carcinoma. *Oncol Rep*. 2005. Mar; 13(3):433-438. (SCI; I.F.: 2.976; Oncology: 123/222 = 55.41%)
43. Hsiao HH, **Yang MY**, Chang JG, Liu YC, Liu TC, Chang CS, Chen TP, Lin SF. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. *Cancer Chemoth Pharm*. 2004. 53(5): 445-451. (SCI; I.F.: 2.808; Pharmacology and Pharmacy: 107/260 = 41.15%)
44. **Yang MY**, Liu TC, Chang JG, Lin PM, Lin SF. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. *Blood*. 2003. 101(8): 3205-3211. (SCI; I.F.: 15.132; Hematology: 2/71 = 2.82%)
45. Liu TC, Lin SF, Chang JG, **Yang MY**, Hung SY, Chang CS. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukemia. *Brit J Haematol*. 2003. 123: 654-661. (SCI; I.F.: 5.128; Hematology: 12/71 = 16.90%)
46. **Yang MY**, Chuang H, Chen RF, Yang KD. Reversible phosphatidylserine expression on blood granulocytes related to membrane perturbation but not DNA strand breaks. *J Leukocyte Biol*. 2002. 71(2): 231- 237. (SCI; I.F.: 4.224; Hematology: 18/71=25.35%)
47. Kuo YR, Yang KD, **Yang MY**, Huang MNL, Lin CW, Lin FC, Wei FC, Jeng SF. Reactive thrombocytosis alone does not affect the patency of microvascular anastomosis in the splenectomy rat. *Plast Reconstr Surg*. 2002. 110(3):812-7. (SCI; I.F.: 3.475; Surgery: 30/200 =15.00%)
48. Li CC, **Yang MY**, Chen RF, Lin TY, Tsao KC, Ming HC, Liu HC, Lin SF, Yeh WT, Chu YT, Yang KD. Clinical manifestations and laboratory assessment in an Enterovirus 71 outbreak in southern Taiwan. *Scand J Infect Dis*. 2002. 34(2): 104-9. (SCI; I.F.: 2.201; Infectious Diseases: 56/84 = 66.67%)
49. Yang KD, **Yang MY**, Li CC, Lin SF, Chong MC, Wang CL, Chen RF, Lin TY. Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. *J Infect Dis*. 2001. 183(6): 850-856. (SCI; I.F.: 5.186, Infectious Diseases: 9/88 = 10.23%)
50. Yang KD, Yeh WT, **Yang MY**, Chen RF, Shaio MF. Antibody-dependent enhancement of hetero- typic dengue infections involved in suppression of IFN γ production. *J Med Virol*. 2001. 63(2): 150-157. (SCI; I.F.: 1.988; Virology: 25/35=71.43%)

51. Chen RF, Yeh WT, **Yang MY**, Yang KD. A model of the real-time correlation of viral titers with immune reactions in antibody-dependent enhancement of dengue-2 infections. *FEMS Immunol Med Microbiol. (Pathogens Dis)* 2001. 30(1): 1-7.
(SCI; I.F.: 2.337; Infectious Diseases: 53/88= 60.23%)
52. Yang KD, Chen MZ, Teng RJ, **Yang MY**, Liu HC, Chen RF, Hsu TY, Shaio MF. A model to study antioxidant regulation of endotoxemia-modulated neonatal granulopoiesis and granulocyte apoptosis. *Pediatr Res.* 2000. 48(6): 829-834. (SCI; I.F.: 3.123; Pediatrics: 16/124 = 12.90%)
53. Huang HC, **Yang MY**, Huang CB, Yang KD. Profiles of inflammatory cytokines in bronchoalveolar lavage fluid from premature infants with respiratory distress disease. *J Microbiol Immunol Infect.* 2000. Mar; 33(1): 19-24. (SCI; I.F.: 2.094; Microbiology: 81/124= 65.32%)
54. Yu HR, **Yang MY**, Yeh WT, Yang KD. Common variable immunodeficiency with mosaic trisomy 8: report of one case. *Acta Paediatr Taiwan.* 2000. 41(6): 331-335.
55. Popp RA, Popp DM, Shinpock SG, **Yang MY**, Mural JG, Aguinaga MdP, Kopsombut P, Roa PD, Turner EA, Rubin EM. Atransgenic mice model of hemoglobin s antilles disease. *Blood.* 1997. 89(11): 4204- 4212. (SCI; I.F.: 15.132; Hematology: 2/71 = 2.82%)
56. **Yang MY**, Pu HF, Jeng FS, Wang SW, Ho LL, Wang PS. Effect of thyroidectomy on the release of prolactin in vitro response to calcitonin. *Chinese J Physiol.* 1988. 31(2):105-12.
(SCI; I.F.:0.827; Physiology: 75/83 = 90.36%)
57. Pu HF, **Yang MY**, Wang SW, Kao YC, Jeng FS, Wang PS. Effects of thyroidectomy on the metabolic clearance rate of prolactin and prolactin release in the rat. *Chinese J Physiol.* 1987. 30(1):15-24.
(SCI; I.F.:0.827; Physiology: 75/83 = 90.36%)

B、研討會論文

1. CH Yang, CF Hwang, **MY Yang**, PM Lin, JH Chuang. **2015**. Expression of Toll-like receptor genes in leukocytes of patients with sudden sensorineural hearing loss. 30th Politzer Society Meeting/ 1st World Congress of Otology, Niigata, Japan.
2. **Yang MY**, Chang JG, Chen IY, Lin PM, Hsiao HH, Liu YC, Yang WC, Lin SF. **2013**. Imprinted non-coding rna genes, *H19* and *ZNF215*, are potential markers for two-year survival for acute myeloid leukemia patients with normal and abnormal karyotypes. 55th ASH Annual Meeting and Exposition. New Orleans, LA, USA. December 5-10. (*Blood* 2013; 122(21): Abstract 2605)
3. Hsu CM, Lin PM, Lai CC, Lin HC, Lin SF*, **Yang MY**. *PER1* and *CLOCK* are potential circulating biomarkers for head and neck squamous cell carcinoma. **2012**. 93rd Annual academic meeting, Taiwan Otolaryngological Society, Kaohsiung, Nov 10.
4. **Yang MY**, Chang JG, Lin PM, Hsu JF, Wu CH, Yang WC, Liu YC, Hsiao HH, Lin SF. **2011**. Altered Regulation of Imprinted Non-coding RNA Genes in Acute Myeloid Leukemia. 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA. December 10-13. (*Blood* 2011; 118(21): Abstract 3456)
5. Liu YC, Yang YH, Hsiao HH, **Yang MY**, Yang WC, Lin SF. **2011**. Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies — A population-based matched-control study in Taiwan. 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA. December 10-13. (*Blood* 2011; 118(21): Abstract 1599)
6. **Yang MY**, Yang WC, Lin PM, Hsu JF, Hsiao HH, Liu YC, Tsai HJ, Chang CS, Lin SF. **2010**. Regulation of Genes of the Circadian Clock in Human Chronic Myeloid Leukemia: Abolished Daily Oscillation of *PER1*, *PER2*, *PER3* and *CRY2*. 52nd ASH Annual Meeting and Exposition. Orlando, FL, USA. Decmber 4-7. (*Blood* 2010; 116(21): 3633)
7. **Yang MY**, Yang WC, Lin PM, Hsu JF, Hsiao HH, Liu YC, Tsai HJ, Chang CS, Lin SF. **2010**. Induction of Senescence by Doxorubicin is Associated with Upregulated miR-375 and Induction of Autophagy in CML Cell Line K562. 52nd ASH Annual Meeting and Exposition. Orlando, FL, USA. Decmber 4-7. (*Blood* 2010; 116(21): 1843)
8. 李文欽、**楊敏瑜**、廖明一 **2009** 利用同步定量反轉錄聚合酶連鎖反應建立抗藥性結核分枝桿菌篩檢技術；生化工程年會；中興大學；六月 6~7 日
9. 陳宗儒、**楊敏瑜**、廖明一 **2009** 建立分支桿菌及多重抗藥性分支桿菌篩選技術；生化工程年會；中興大學；六月 6~7 日
10. 陳勇秀、**楊敏瑜**、廖明一 **2008** 利用同步定量聚合酶連鎖反應建立抗藥性分枝桿菌篩檢技術；生化工程年會；元智大學；六月 25~26 日
11. 李宗翰、**楊敏瑜**、廖明一 **2008** 利用同步定量聚合酶連鎖反應進行豬瘟疫苗之效價分析；生化工程年會；元智大學；六月 25~26 日
12. 曾倍君、**楊敏瑜**、廖明一 **2008** 急性骨髓性白血病患者三十例之染色體病例討論；生化工程年會；元智大學；六月 25~26 日
13. 李煒明、**楊敏瑜**、連偉成、江正榮、廖明一 **2006**. 利用同步定量聚合酶連鎖反應進行卡介苗之效價分

析；輔英科技大學第一屆環境與生命學術研討會暨九十四年度教師學術成果發表會；輔英科技大學；五月 25~26 日

14. 李煒明、楊敏瑜、連偉成、江正榮、廖明一 **2006**. Potency Analysis of BCG Vaccine using Real-Time Quantitative Polymerase Chain Reaction. 生化工程年會；清華大學；六月 23~24 日
15. Lin SF, Yang MY, Chang JG, Yang WC, Liu TC. **2005**. Daily expression of circadian gene expression rhythm was abolished in peripheral blood cells of chronic myeloid leukemia. The Annual Meeting of Association of Experimental Hematology. Glasgow, UK. July 14-16.
16. Lin SF, Yang MY, Chang JG, Liu TC, Chen TP. **2004**. Downregulation of Circadian Clock Genes in Chronic Myeloid Leukemia: Alternative Methylation Pattern of *hPER3*. The 46th Annual Meeting of American society of Hematology. San Diego, CA, USA. December 4-7.
17. Lin SF, Yang MY, Chang JG, Liu TC, Chen TP. **2004**. Epigenetic Alteration of Circadian genes, *PER1*, *PER2*, and *PER3*, in Chronic Myeloid Leukemia. The Annual Meeting of American Society of Clinical Oncology. Chicago, IL, USA. April 20-22.
18. Lin SF, Yang MY, Chang JG, Liu TC, Chen TP. **2003**. Expression of circadian genes in chronic myeloid leukemia. The 45th Annual Meeting of American society of Hematology. San Diego, CA, USA. December 6~9. (*Blood*, 102 (11): 583a; Abstract number 2148)
19. Yang MY, Chang JG, Liu TC, Chen TP, Lin SF. **2003**. JunB Expression Is Inactivated By Methylation In Human Acute Lymphoid Leukemia. 27th Annual Meeting of the Hematology Society of Taiwan and Society of Blood and Marrow Transplantation, ROC at Kaohsiung, Taiwan. March 15-16.
20. Lin SF, Yang MY, Liu TC, Chang JG, Chen TP. **2002**. JunB expression is inactivated by methylation in acute myeloid leukemia. 2002. The 44th Annual Meeting of American society of Hematology. Philadelphia, PA, USA. December 6~10.
21. Lin SF, Yang MY, Liu TC, Su YC, and Chen TP. **2001**. Down regulation of JunB expression in human leukemia. The 43rd Annual Meeting of The American Society of Hematology. Orlando, Florida, USA. December 7-11.
22. Su YCe, Yang MY, Liu TC, Chen TP, Lin SF. **2001**. Down regulation of JunB expression in leukemia. 兩岸學術交流研討會. Shanghai, China. August.
23. 楊崑德, 楊敏瑜, 葉文婷, 王志祿, 劉秀金. 重症腸病毒患者 T 細胞反應與 T-B 細胞間橋分子(CD40-L) 表現之變化. **1999**. Abstract in the 157th Scientific Meeting of The Chinese Taipei Pediatric Association. Taipei, Taiwan, April.
24. Liu HC, Yang MY, Yang KD. Apoptosis of neonatal neutrophils as determined by phosphatidylserine expression. **1998**. Abstract in the 4th Scientific Meeting of The Chinese Taipei Neonatology Association, Kaohsiung, Taiwan, March.
25. Yang MY, Liu HC, Huang CP, Yang KD. Dose phosphatidylserine (PS) appropriately reflect human neutrophil apoptosis? **1998**. Abstract in the 153rd Scientific Meeting of The Chinese Taipei Pediatric Association, Taipei, Taiwan, April.
26. Lin SF, Chen TP, Yang MY, Chang CS, Liu TC, Huang SM. **1997**. Clinical pharmacological study of rhG-CSF on mobilization of peripheral blood stem cells following CHOP chemotherapy in patients with non-Hodgkin's lymphoma. 21st Annual Meeting of the Hematology Society of Taiwan and Society of Blood and Marrow

Transplantation, ROC at Kaohsiung, Taiwan. March 15-16.

27. Chang CS, **Yang MY**, Lin SF, Liu TC, Huang SM, Chen TP, Liu HW. **1997**. Immunophenotype analysis of cord blood mononuclear cells. 21st Annual Meeting of the Hematology Society of Taiwan and Society of Blood and Marrow Transplantation, ROC at Kaohsiung, Taiwan. March 15-16.
28. Popp RA, Popp DM, **Yang MY**, Overcash ME, Shinpock SG. **1995**. Flow cytometric and immunological studies on animal models of human diseases. South Central Flow Cytometry Association Meeting at Little Rock, AK, USA. May 4-6.
29. **Yang MY**, Popp DM, Popp RA. **1994**. The route of retroviral transmission in B10.F mice identified by flow cytometric methods that detect cell surface MuLV antigen expression. South Central Flow Cytometry Association Meeting at Nashville, TN, USA. May 20-21.
30. Popp DM, **Yang MY**, Poole T, Popp RA. **1994**. Quantitation and characterization of MuLV infected lymphoid cells using flow cytometry. January 18-21. International Cytometry Symposium at San Francisco, CA, USA.
31. **Yang MY**, Popp DM, Popp RA. **1993**. Flow cytometric identification of cellular MuLV expression on lymphoid cells from one-month-old B10.F. mice. *J Immunol* 150(8):159A.
32. Wang TH, Yang WK, Saavedra HI, Yang DM, Popp DM, Hoyt PR, Chang LY, **Yang MY**. **1992**. Effect of retroviral long terminal repeat (LTR)-containing transgenes on thymic lymphoma induction in FVB/N mice neonatally treated with 5-azacytidine. AACR meeting at San Diego, CA, USA. May 14-16.
33. Lee JN, Wang TH, **Yang MY**. **1988**. Human placenta contains litocin--A novel neuro- hypophyseal hormone. 8th International Congress on Endocrinology at Kyoto, Japan. July 17-23.
34. Lee JN, Wang TH, **Yang MY**. **1987**. Litocin--A novel neurohypophyseal hormone in human placenta. 6th International Congress on Placental and Endometrial Proteins at Nagoya, Japan. Dec. 1-3.
35. Wang TH, **Yang MY**, Chong JY, Wang HS, Lee JN. **1987**. Oxytocin and AVP levels in human ovarian cycle. 27th Annual Convention of the Association of OB/GYN of R.O.C. at Taipei, Taiwan. Feb. 15.
36. Chu ML, **Yang MY**, Shieh MH, Wu YC, Chang SA. **1986**. Antibacterial activity of antibiotics against *Neisseria gonorrhoeae* isolated in Taiwan. Second World Congress on Sexually Transmitted Disease at Paris, France. June 25-28.

C、專書

1. **Yang MY.** 2004. Molecular mechanism of Leukemogenesis – The role of *JunB* gene. (博士論文)
2. **Yang MY.** 1994. Flow cytometric identification of virally infected cells and altered production of TH1 and TH2 cytokines in viremic B10.F mice. (碩士論文)

D、教科書翻譯

1. 生物學 (原著：Essential Biology by Campbell et al, 2nd Ed, 2007)，第三章：生命分子，第四章：細胞之旅
2. 生物學 (原著：Essential Biology by Campbell et al, 5th Ed, 2013)，第三章：生命分子，第四章：細胞之旅第六章：細胞呼吸作用：有氧狀態獲取的食物能量

研究計畫明細

計畫名稱	補助或委託機構	起訖年月	執行情形	計畫內擔任的工作	經費總額
使用小鼠模式探討日夜節律失衡對肥胖的影響 (MOST 107-2320-B-182-022-)	科技部	2018/08/01 至 2019/07/31	執行中	主持人	\$700,000
以動物模式探討益生菌 <i>Clostridium butyricum miyairi</i> 預防大腸直腸癌之可能性 (CMRPD8H0011)	長庚醫院	2018/07/01 至 2019/06/30	執行中	主持人	\$900,000
生理時鐘破壞對於噪音暴露後耳蝸的影響 (MOST 107-2314-B-182A-083 -) 楊昭輝	科技部	2018/08/01 至 2019/07/31	執行中	共同主持人	\$980,000
血管收縮素受體阻斷劑對鼻咽癌細胞蛋白質體與微小核糖核酸調控之機轉:臨床及體內與體外研究 (MOST 107-2314-B-182A-127-MY2) 林右才	科技部	2018/08/01 至 2019/07/31	執行中	共同主持人	\$2,020,000
阻塞性睡眠呼吸中止症患者日夜節律基因轉譯-轉錄迴饋迴路變動的上游調控 (MOST 107-2314-B-182A-086 -) 林新景	科技部	2018/08/01 至 2019/07/31	執行中	共同主持人	\$760,000
睡眠障礙和生理時鐘基因表現改變對裝置心臟節律器病人發生心房顫動的影響 (MOST 107-2314-B-182A-151 -) 陳永隆	科技部	2018/08/01 至 2019/07/31	執行中	共同主持人	\$947,000
探討大黃蘗昆類衍生物誘發鼻咽癌細胞凋亡與細胞自噬相關機轉之體外研究 (CMRPG8G1501) 林右才	長庚醫院	2018/01/01 至 2018/12/31	執行中	共同主持人	\$850,000
慢性鼻竇炎鼻腔上皮組織細胞激素物質與微核糖核酸調控相關性及氧耗損之研究 (1/2) (CMRPG8G0791) 林右才	長庚醫院	2017/09/01 至 2018/08/31	已結案	共同主持人	\$1,000,000
探討日夜節律在後天性聽力障礙之角色 (3/3) (CMRPG8E01483) 楊昭輝	長庚醫院	2017/12/01 至 2018/11/30	執行中	共同主持人	\$600,000
阻塞性睡眠呼吸中止症患者手術治療前後表觀遺傳調控表現之變化 (CMRPG8F1281) 林新景	長庚醫院	2017/01/01 至 2017/12/31	已結案	共同主持人	\$950,000
探討日夜節律在後天性聽力障礙之角色 (2/3) (CMRPG8E01482) 楊昭輝	長庚醫院	2016/12/01 至 2017/11/30	已結案	共同主持人	\$600,000
探討日夜節律基因在頭頸癌中標靶藥物治	長庚醫院	2016/11/01	已結案	共同主持人	\$982,755

計畫名稱	補助或委託機構	起訖年月	執行情形	計畫內擔任的工作	經費總額
療之角色及尋找新的治療模式 (CMRPG6F0511) [徐正明]		至 2017/10/31			
調升PER3基因表現以增加白血病對藥物敏感性之可能性及其機轉之探討 (CMRPD8F0761)	長庚醫院	2016/09/01 至 2017/12/31	已結案	主持人	\$1,212,145
日夜節律與先天免疫相關基因在周邊性眩暈病理機轉之角色 (MOST 105-2314-B-182A-074 -) [楊昭輝]	科技部	2016/08/01 至 2017/07/31	已結案	共同主持人	\$840,000
探討日夜節律在後天性聽力障礙之角色 (1/3) (CMRPG8E01481) [楊昭輝]	長庚醫院	2015/12/01 至 2016/11/30	已結案	共同主持人	\$600,000
日夜節律基因異常與癌症發生之分子調控機轉探討(2) (MOST 104-2320-B-182-018)	科技部	2015/08/01 至 2016/07/31	已結案	主持人	\$740,000
阻塞性睡眠呼吸中止症手術治療前後相關日夜節律基因表現之變化 (第二年) (MOST 104-2314-B-182A-074-) [林新景]	科技部	2015/08/01 至 2016/07/31	已結案	共同主持人	\$1,170,000
探討先天免疫反應在胺基酸甘醣體引起之耳毒性內耳細胞的角色 (MOST 104-2314-B-182A-057) [楊昭輝]	科技部	2015/08/01 至 2016/07/31	已結案	共同主持人	\$750,000
血液惡性腫瘤異常印記非編碼核糖核酸基因表現機轉之探討 (2) (MOST 104-2314-B-037 -035) [林勝豐]	科技部	2015/08/01 至 2016/07/31	已結案	共同主持人	\$900,000
急性骨髓性白血病異常印記非編碼核糖核酸基因表現機轉之探討 (CMRPD8E0171)	長庚醫院	2015/06/01 至 2016/05/31	已結案	主持人	\$1,000,000
評估新式甲殼素合併富含缺氧誘導間質幹細胞分泌液合成敷料促進糖尿病癒合之生物機轉研究 (2/2) (CMRPD8D0292)	長庚醫院	2015/06/01 至 2016/12/31	已結案	主持人	\$1,200,000
日夜節律基因異常與癌症發生之分子調控機轉探討 (MOST 103-2320-B-182-023-)	科技部	2014/08/01 至 2015/07/31	已結案	主持人	\$750,000
阻塞性睡眠呼吸中止症手術治療前後相關日夜節律基因表現之變化 (MOST 103-2314-B-182A-060-) [林新景]	科技部	2014/08/01 至 2015/10/31	已結案	共同主持人	\$900,000
探討日夜節律基因在頭頸癌細胞的功能性角色及新治療策略的可能性(二)	科技部	2014/08/01 至	已結案	共同主持人	\$850,000

計畫名稱	補助或委託機構	起訖年月	執行情形	計畫內擔任的工作	經費總額
(MOST 103-2314-B-182A-063-) [徐正明]		2015/07/31			
二十四小時日夜節律異常與癌症發生之分子調控機轉探討 [CMRPG8C0911]	長庚醫院	2014/03/01 至 2015/2/28	已結案	主持人	\$700,000
血液惡性腫瘤異常印記非編碼核糖核酸基因表現機轉之探討 (MOST 102-2314-B-037-066-MY2) [林勝豐]	科技部	2013/08/01 至 2015/07/31	已結案	共同主持人	\$2,240,000
探討日夜節律基因在頭頸癌細胞的功能性角色及新治療策略的可能性 (MOST 102-2314-B-182A-083-) [徐正明]	科技部	2013/08/01 至 2014/07/31	已結案	共同主持人	\$800,000
探討急性骨髓性白血病之印記基因表現機轉 [CMRPG8B0661]	長庚醫院	2012/08/01 至 2014/02/28	已結案	主持人	\$1,000,000
以超基因觀點來探討印記基因非編碼核糖核酸及頭頸 癌症的關聯性 (MOST 101-2314-B-182A-051-) [徐正明]	科技部	2012/08/01 至 2013/07/31	已結案	共同主持人	\$700,000
血液惡性腫瘤表觀基因組改變之研究 (MOST 101-2314-B-037-041-) [林勝豐]	科技部	2012/08/1 至 2013/07/31	已結案	共同主持人	\$900,000
從功能性研究探討印記基因在頭頸癌症的致病機轉 [CMRPG8B0361] [徐正明]	長庚醫院	2012/08/1 至 2014/07/31	已結案	共同主持人	\$1,800,000
探討急性骨髓性白血病之印記基因表現機轉 [CMRPD8B0661]	長庚醫院	2012/11/01 至 2013/10/31	已結案	主持人	\$1,000,000
印記非編碼核糖核酸在頭頸癌症之角色 (MOST 100-2314-B-182A-023-) [林勝豐]	科技部	2011/08/1 至 2012/07/31	已結案	共同主持人	\$650,000
探討二十四小時日夜節律與細胞代謝之間的連結與調控在腫瘤生成的角色 [CMRPD8A0491]	長庚醫院	2011/11/1 至 2012/10/31	已結案	主持人	\$1,049,200
MicroRNA 在細胞老化之表現與功能之研究 [CMRPD880021/CMRPD880022]	長庚醫院	2009/10/01 至 2011/9/30	執行中	主持人	\$2,537,160
細胞老化基因調控與細胞癌化之研究 [MOST 96-2320-B-182-037-MY3]	科技部	2007/08/1 至 2010/07/31	已結案	主持人	\$3,436,000

計畫名稱	補助或委託機構	起訖年月	執行情形	計畫內擔任的工作	經費總額
骨髓化生不良症候群與細胞老化基因調控和其疾病進程關係之研究 (MOST 96-2314-B-037-019-MY3) 林勝豐	科技部	2007/08/1 至 2010/07/31	已結案	共同主持人	\$3,480,000
結核菌及多重抗藥性結核菌篩檢技術 (KCGDOH97007)	高雄市政府 衛生局	2008/01/01 至 2008/12/31	已結案	共同主持人	\$880,000
建立結核菌抗藥性篩檢技術	高雄市政府 衛生局 疾病管制處	2007/01/01 至 2007/12/31	已結案	共同主持人	\$900,000
龜殼花毒液中主要毒素抗原之鑑定、抗蛇毒血清中和力價快速篩檢平臺之建立及提升馬匹抗蛇毒血清中和力價之研究	行政院 衛生署 疾病管制局	2007/01/01 至 2007/12/31	已結案	共同主持人	\$900,000
利用同步定量聚合酵素連鎖反應建立快速卡介苗效價分析技術 (MOST 95-2622-B-242-001-CC3)	科技部	2006/11/1 至 2007/10/31	已結案	主持人	\$498,000
p53-PUMA-BIM-SLUG 死亡連絡徑路在使用 Imatinib mesylate 治療慢性骨髓性白血病病人之角色 (MOST 95-2314-B-037-072-) 林勝豐	科技部	2006/08/1 至 2007/07/31	已結案	共同主持人	\$1,080,000
Yin Yang 1 基因在白血病生成中所扮演的角色 (MOST 94-2314-B-242-001-)	科技部	2005/01/01 至 2005/07/31	已結案	主持人	\$496,800